{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"3.910","floor":"2.950"},"ipodate":{"start":"2010-04-27 00:00:00","end":"2010-04-30 00:00:00"},"minimumcapital":"3949.46","subscribed":"853.00","marketcap":"16.23億","H_marketcap":"--","pe":"--","codesrate":"10.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/00503/LTN20100427130_C.pdf","ipopricing":"3.910","resultdate":"2010-05-06 00:00:00","enddate":"2010-04-30 00:00:00","listeddate":"2010-05-07 00:00:00","issuenumber":"14135.00萬","issuenumberhK":"7067.50萬","issuenumberother":"7067.50萬","grayprice":"--","sponsors":"派杰亞洲有限公司","raisemoney":"30450.00萬","use":"1、約91.4百萬港元，將撥支作產品開發及研究；\n2、約106.6百萬港元，將撥支作收購及╱或購買生產技術或新藥物的已授出批文的權利；\n3、約39.6百萬港元，將撥支作擴充原料生產設施；\n4、約39.6百萬港元，將用作增加我們的核心產品的醫院覆蓋率至一至三級醫院；\n5、約27.3百萬港元，用作一般營運資金用途。","shares":1000,"leadagent":"派杰亞洲證券有限公司","bookrunners":"派杰亞洲證券有限公司","coordinator":"","firstDayOpen":"4.80","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"派杰亞洲證券有限公司","code":"E00503","name":"朗生醫藥","fullname":"朗生醫藥控股有限公司"},"institutioninfo":{"principaloffice":"香港德輔道中189號李寶樁大廈12樓1203-4室","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333","chairman":"吳鎮濤","secretary":"彭啟輝","telephone":"(852) 2828 9285","substantialshareholders":"Cathay International Holdings Limited(51.66%)","principalactivities":"開發、生產及銷售治療風濕免疫疾病的專科處方西藥，亦生產及銷售其他藥品。","website":"http://www.lansen.com.cn"},"managerinfo":[],"investorinfo":[],"TotalShareholdingPercentage":0},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":507}